Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026
Same author

Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma.

Cancer research communications·2026
Same author

Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination Survey.

Blood cancer journal·2026
Same author

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Blood advances·2026
Same author

Proteomic profiling revealed unique disease biology associated with 1q abnormalities in multiple myeloma.

NPJ precision oncology·2026
Same author

Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel.

Blood advances·2026

Related Experiment Video

Updated: Jul 14, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Individualizing therapy using molecular markers in multiple myeloma.

P Leif Bergsagel1

  • 1Mayo Clinic, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, USA. bergsagel.leif@mayo.edu

Clinical Lymphoma & Myeloma
|June 29, 2007
PubMed
Summary

Multiple myeloma genetics impact patient outcomes. Risk stratification guides therapy, deferring stem cell transplant for high-risk patients and tailoring treatment based on response.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: Jul 14, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Multiple myeloma is a complex, heterogeneous plasma cell malignancy.
  • Genetic abnormalities are key drivers of multiple myeloma pathogenesis and prognosis.
  • Current risk stratification identifies distinct genetic subgroups with varying prognoses.

Purpose of the Study:

  • To analyze the prognostic significance of genetic events in multiple myeloma.
  • To propose a risk-adapted therapeutic strategy for multiple myeloma patients.
  • To optimize treatment sequencing based on individual risk profiles.

Main Methods:

  • Review of genetic data in multiple myeloma patients.
  • Classification of genetic events into 'good' and 'poor' risk categories.
  • Assessment of proliferation markers (e.g., plasma cell labeling index, beta(2)-microglobulin, gene expression profiling).

Main Results:

  • Approximately 75% of patients have good-risk genetics (hyperdiploidy, cyclin D translocations) and benefit from standard therapy.
  • Approximately 25% of patients have poor-risk genetics (t(4;14), MAF translocations, p53 deletion, hypodiploidy) or high proliferation, with limited benefit from current approaches.
  • Proliferation is an independent poor-risk feature not captured by genetic markers.

Conclusions:

  • Genetic profiling and proliferation assessment are crucial for multiple myeloma risk stratification.
  • A risk-adapted therapy approach, including deferred stem cell transplantation for high-risk patients, is proposed.
  • Individualized treatment timing and sequencing based on response are essential for optimizing outcomes.